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Abstract
Background: Formalin injection into rodent hind paws is one of the most commonly employed pain assays. The
resulting nocifensive behaviors can be divided into two phases differing in timing, duration and underlying
mechanisms. Spinal sensitization has long been felt to participate in the second phase of this response, although
this sensitization is incompletely understood. By using correlative analysis between spinal gene expression and
mouse strain-dependent intensity of late phase behavior, we hypothesized genes participating in variability of the
response could be identified.
Results: Late phase formalin behavior scores among 10 inbred mouse strains were correlated with a spinal cord
gene expression database constructed using expression arrays. Messenger RNA levels for several genes were highly
correlated with the late phase behavioral responses. Most of these genes had already been implicated in
mechanisms regulating pain and analgesia. One of the most strongly correlated genes, Mapk8 coding for c-Jun
N-terminal kinase 1 (JNK1), was chosen for further analysis. Studies using additional strains of mice confirmed that
spinal cord mRNA expression levels of Mapk8 followed the pattern predicted by strain-specific levels of formalin
behavior. Interestingly, spinal cord JNK1 protein levels displayed an inverse relationship with mRNA measurements.
Finally, intrathecal injections of the selective JNK inhibitor, SP600125, selectively reduced late phase licking
behavior.
Conclusions: Wide differences in pain behaviors, including those resulting from the injection of formalin, can be
observed in inbred strains of mice suggesting strong genetic influences. Correlating levels of gene expression in
tissues established to be mechanistically implicated in the expression of specific behaviors can identify genes
involved in the behaviors of interest. Comparing formalin late phase behavior levels with spinal cord gene
expression yielded several plausible gene candidates, including the Mapk8 gene. Additional molecular and
pharmacologic evidence confirmed a functional role for this gene in supporting formalin late phase responses.
Background
The injection of formalin into the skin of rodent hind
paws to cause spontaneous pain-related (nocifensive)
behaviors is one of the most commonly used animal
pain assays [1]. This test was introduced in 1977 as a
method that allowed nocifensive behaviors to be studied
without restraint, and with a continuous rather than
transient source of stimulation [2]. This model can be
distinguished from many other irritant pain models–for
example, ones involving the administration of carragee-
nan, bee venom, capsaicin and other compounds–by the
existence of a biphasic response. An intense first (early)
phase of hindpaw shaking and licking subsides
approximately 5-10 minutes after formalin injection,
only to have the behaviors reappear and last another 30
minutes or longer. The first phase of this test is thought
to be due to direct effects of formalin on nociceptive
fibers [3], and recent evidence suggests that the Transi-
ent receptor potential cation channel 1 (TRPA1) recep-
tor/ion channel might mediate that signal transduction;
TRPA1-deficient mice and mice administered a selective
TRPA1 antagonist display greatly reduced early phase
formalin-induced behaviors [4]. Formalin early phase
behavior are sensitive to reversal by analgesics such as
opioids and paracetamol [3,5].
The second (late) phase of the formalin response,
sometimes referred to as the “inflammatory phase,” has
classically been ascribed to inflammation as non- * Correspondence: djclark@stanford.edu
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acid, ibuprofen and ketoprofen are active in reducing
the associated behaviors [5,6]. However, many drugs
without anti-inflammatory activity are also active in this
phase including gabapentin,l a m o t r i g i n e ,n i t r i co x i d e
synthase (NOS) inhibitors and others [7,8]. Further
exploration of the basis for late phase nocifensive beha-
viors has revealed that sensitization of dorsal horn neu-
rons is involved [9,10]. In fact, the intrathecal injection
of many agents reduces late phase behaviors. Late phase
behavior is also of interest because of the similarities in
presumed mechanism between it and some dimensions
of neuropathic pain [11].
Large inter-individual differences exist between both
humans and animals with respect to pain, nociceptive
sensitivity and analgesic responses [12]. That genetics
mediates a significant percentage of inter-strain variance
in commonly used mouse pain assays has been firmly
established. The formalin test when applied to inbred
mice leads to highly strain-dependent results for both
early and late phase behaviors [13,14]. Such inter-strain
differences have been exploited using quantitative trait
locus (QTL) mapping, haplotypic analysis and other
techniques to gain insight into the identity of the trait-
relevant genes. For example, one recent report used
both QTL and haplotypic analyses to demonstrate that
the early phase of the formalin response was dependent
on the activity of afferent neuron ATPase activity, pre-
sumably related to the ability of the neuron to maintain
an electrochemical gradient supporting neuronal firing
[15]. The heuristic value of the approach was illustrated
by the fact that the relevant gene was Atp1b3 [15],
encoding a little-studied b subunit of the ATPase rather
than the catalytic a subunit. Genetics based studies have
not yet been published demonstrating how particular
genes might be responsible for the wide differences
between strains in their late phase behavior despite the
importance of this response.
An alternative technique for identifying genes poten-
tially involved in regulating a phenotype of interest is to
correlate expression of the phenotype, such as a pain-
related nocifensive behavior, with the expression level of
g e n e si nat i s s u ek n o w nt ot a k ep a r ti nc o n t r o l l i n gt h e
phenotype [16,17]. The assumptions underlying this
approach are that the abundance of mRNA for at least
some controlling genes will be either positively or nega-
tively correlated with the phenotype of interest, and that
the correlation reflects a functional role for the gene in
the phenotype. This “expression QTL” or “genetical
genomics” technique is particularly attractive as any
number of phenotypes couldb ec o m p a r e dw i t he x p r e s -
sion databases for specific tissues. Here we use such an
approach to identify candidate genes controlling late
phase formalin induced nocifensive behavior in inbred
strains of mice.
Results
Inter-strain differences in formalin-induced nocifensive
behaviors
Early and late phase responses to subcutaneous hind
paw formalin injection were determined for 17 strains of
inbred mice. The results demonstrated large differences
between strains for both phases during the period of
observation (Figure 1). The strain specific licking/biting
times were converted to z-scores for the purpose of per-
forming subsequent correlative analysis, and those
scores appear in Table 1. Correlational analysis of the
rank order of responses for the two phases revealed no
significant statistical correlation (Spearman r = 0.22, p >
0.05).
Late phase formalin response intensity versus spinal cord
gene expression
In preparatory experiments we constructed a spinal cord
gene expression database using material from 10 of the
17 strains of inbred mice tested behaviorally. In order to
enrich our correlational analysis in associations with
strongly differentially expressed genes, and to minimize
false-positive associations, probesets were first selected
showing 3-fold or greater differential expression across
those 10 strains. Thus, data from the >45,000 probesets
represented on the array chips was first refined to a
group of 2,500 probesets.
Table 1 Z-Scores for mouse strain specific formalin
induced licking behavior.
Strain Phase I
z-score
Phase II
z-score
129 0.17 -0.64
A -0.39 -0.81
AKR 0.18 -0.11
B10.D2 -0.14 0.47
BALB/c -0.42 -0.19
BTBR -0.36 -0.33
C3H -0.03 -0.16
C57 0.38 0.76
C58 -0.59 0.77
CBA 0.53 1.22
DBA 0.08 -0.01
FVB -0.24 0.06
LP -0.07 -1.18
MRL -1.22 0.26
NOD 0.71 0.09
NZB 0.32 -0.78
NZW -1.15 -0.40
These values were calculated based on the percent licking data for early and
late phase presented in Figure 1.
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genes associated with the intensity of formalin late
phase behavior. Pearson correlational analysis between
late phase behavior and the refined group of 2,500
probesets identified several strongly associated genes.
The 5 strongest associations are displayed in Table 2.
For 3 of the 5 associations the direction of correlation
was negative (lower expression with higher levels of late
Figure 1 Formalin-induced nocifensive behaviors. Video recordings of mice licking/biting after plantar hind paw injection of formalin were
reviewed for 17 strains of inbred mice (n = 10-25/strain). Bars represent the mean ± S.E.M. percentage of samples featuring licking/biting in
early (0-5 min; graph A) and late phase (10-60 min; graph B).
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forms of the identified genes, had been previously asso-
ciated with pain or analgesia-related behaviors in rodent
pain models (see references in Table 2). For 2 of the
genes, coding for cytosolic phospholipase A2 and the
SCN2B sodium ion channel subunit, a role for their pro-
tein in controlling late phase formalin behavior had
been previously reported. Because the Mapk8 gene, cod-
ing for c-Jun N-terminal kinase 1 (JNK1), was also
strongly associated with spinal pain mechanisms but has
been less strongly investigated with respect to control-
ling formalin late phase behaviors specifically, we chose
to pursue this association further.
The polymorphic nature of the mitogen activated protein
kinase 8 (Mapk8) gene
Using publicly available data, all SNPs within 2 kb of the
Mapk8 gene were identified, totaling 86 SNPs [18]. The
data selected were restricted to the 13 inbred strains of
mice present in that database represented in our experi-
ments. Three distinct haplotypes emerged from this ana-
lysis with 10 strains sharing the most common
configuration of alleles (Figure 2). All three strains hav-
ing unique haplotypes (129/SvIm, LP and NZW/LaC)
displayed late phase responses near the lower end of the
response spectrum.
Haplotypic analysis using the method of Wang et al.
was conducted to determine the degree of association of
the Mapk8 haplotype with the strain specific data [19].
The results showed weak but significant statistical corre-
lation (p =0 . 0 2 9 )w i t hMapk8 haplotype potentially
accounting for 54.4% of the variance in the late phase
data.
Additional mRNA and protein analysis of Mapk8 in spinal
cord tissue
In order to confirm the association of Mapk8 with inter-
strain variability in late phase formalin behavior, ana-
lyses of the spinal cord levels of mRNA and protein
were undertaken. To complete these studies, 4 strains of
mice were chosen for which behavioral data were
available but for which expression array data was not
collected: CBA and C58 (both high formalin late phase
responding), and NZB/Bln and A (both low responding).
In addition, we included the C57BL/6 and 129SvIm
strains for which array data were available. For each of
these strains, spinal cord tissue from adult animals was
harvested and subjected to real-time qPCR. The results
are displayed in Figure 3. The low responding strains
correctly partitioned together as more highly expressing
Mapk8 mRNA, and there was a statistically significant
difference in mRNA levels between the high and low
responding strains.
We went on to complete Western blot experiments to
quantify spinal cord levels of the corresponding JNK1
protein using the same set of strains plus the intermedi-
ate-responding BALB/c strain that was used to normal-
ize the measured protein levels. Figure 3 shows again
that high- and low-responding strains partitioned
together with respect to spinal cord protein levels.
Importantly, mRNA and protein levels were inversely
correlated: strains with low mRNA levels had higher
protein levels. The BALB/c strain had a protein expres-
sion level intermediate to the high and low responding
groups (data not shown). The differences in spinal cord
protein levels of JNK1 between the high and low
responding strains were also statistically significant.
Pharmacological inhibition of JNK1 selectively reduces
late phase formalin behavior
The selective JNK inhibitor, SP600125, was used to test
the functional link between Mapk8 and late phase for-
malin behavior. The drug was injected intrathecally to
target spinal tissue as the relevant source of JNK1 activ-
ity. Figure 4 displays results demonstrating that 50 nmol
SP600125 significantly and selectively reduced late phase
behavior. A higher dose of inhibitor was employed in
additional experiments (150 nmol); no early phase and
no additional late phase inhibition was observed (data
not shown).
Table 2 Genes associated with late phase formalin licking.
Gene Protein Correlation Pain/Analgesia Models References
†
Pla2g4e Phospholipase A2 (PLA2) -0.96 Formalin
Nerve injury
Carrageenan
[27,28,39,40]
[40]
[28,40]
Mapk8 c-Jun N-terminal kinase 1 (MAPK8, JNK1) -0.91 Nerve Injury [20]
RIKEN 4833416E15 (Unknown) 0.90 -
Scn2b Sodium channel beta2 subunit 0.89 Formalin [30]
Kcnj9 G-protein-gated inwardly rectifying K
+ channel subunit 3 (Kir3.3, GIRK3) -0.89 Morphine [41]
The results of correlation analysis between strain-specific late phase formalin scores and a spinal cord gene expression database. The top 5 most-strongly-linked
genes and the proteins they encode, along with the correlation coefficients and the direction of correlation is provided. Positive correlation signifies greater gene
expression corresponding to greater levels of pain behavior.
†References for pain-related investigations specific to the named gene or closely related gene family members.
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The goal of the present studies was to use the emerging
technique of correlating pain-related (nocifensive) beha-
vior across multiple strains of inbred mice with gen-
ome-wide gene expression in a tissue known to regulate
that behavior (i.e., an eQTL or genetical genomics
approach). In this case, the late phase of formalin-
induced nocifensive behavior was correlated with spinal
cord gene expression for 10 strains of mice. Subse-
quently, 4 additional strains were evaluated in
Figure 2 Haplotypic structure of the Mapk8 gene. Using SNP data for the 13 inbred mouse strains, for which it was available, the strains
partitioned into 3 haplotypes. There were 86 SNPs available for this analysis. In this figure blue represents the common allele, yellow represents
the minor allele, and white represents missing alleles.
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were used to quantify mRNA and protein levels respectively. Graph A contains the results of qPCR experiments in which the relative levels of
Mapk8 mRNA for high late phase responding strains were compared with low responding ones. In graph B, similar experiments were performed
using spinal cord protein homogenates. For the protein experiments the spinal cord levels of JNK1 were normalized to the spinal cord levels in
the intermediate-responding BALB/c mice arbitrarily set at a level of 1.0. For all experiments samples from n = 4 mice per strain were analyzed
in triplicate. Bars represent mean ± S.E.M. Three strains within each group were compared to other strain group, *p < 0.05.
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The results of our correlational studies identified several
genes with strongly associated spinal expression pat-
terns. Remarkably, 4 out of the top 5 most-strongly
associated genes, or closely related members of their
gene families, had previously been demonstrated to have
links to pain and analgesia. Subsequent use of mRNA
and protein analysis in additional strains confirmed the
Figure 4 The effects of the JNK inhibitor, SP 600125, on formalin-induced nocifensive behaviors. For these experiments groups of mice
(n = 8) first underwent intrathecal injection of SP 600125 or vehicle 3 h prior to formalin injection. The total duration of licking/biting time
during early (0-5 min) and late phase (10 k-60 min) of the formalin response were measured and averaged for either the entire phase (graph A)
or in 5-min intervals (graph B). Bars and symbols represent mean ± S.E.M. *p < 0.05, ***p < 0.001 compared to the vehicle group.
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JNK1), a spinal cord gene with known roles in neuro-
plasticity. Finally a selective JNK inhibitor blocked late
phase formalin behaviors strongly, with no effect what-
soever on early phase behaviors. In retrospect, no early
phase effects of this drug could be expected, as there
was no statistical correlation between the early phase
and late phase behaviors across the strains tested. Thus,
working with expression and behavioral databases for a
relatively modest number of mouse strains allowed us to
identify highly plausible functionally related genes. The
total number of inbred strains required for these experi-
ments was low compared to the numbers typically
involved in genetic based approaches such as QTL or
haplotypic analyses.
The gene chosen for confirmatory experiments,
Mapk8, has well-established roles in intracellular signal-
ing, including signaling related to nociception. An early
report by Yang et al. [20] used microarray analysis on
rat spinal cord dorsal horn tissue after peripheral axot-
omy to identify JNK1 and other members of the JNK
family as upregulated after nerve injury, though a func-
tional role for these changes was not demonstrated.
Subsequent experiments confirmed that the three splice
variants of JNK (JNK1-3) are highly expressed in spinal
cord tissue [10]. Using spinal nerve ligation to create a
model of neuropathic pain, Zhuang et al. demonstrated
that the up-regulation of JNK1 occurred primarily in
spinal astrocytes, and that the spinal administration of a
selective JNK1 inhibitor blocked the resulting hypersen-
sitivity [21]. Other experiments showed that selective
JNK inhibition reduced nociceptive sensitization in a
model of diabetic neuropathy [22] and after bee venom
or capsaicin injection [23,24]. The suggested mechanism
for activation of JNK1 is via transforming growth factor-
activated kinase 1 (TAK1), a member of the MAPK
kinase family. Spinal knock-down of TAK1 reduces
astrocytic JNK1 phosphorylation in spinal cord tissue
after nerve injury [25]. Additional evidence suggests that
spinal TNFa may work through JNK1 to produce the
cytokine MCP-1, ultimately sensitizing spinal dorsal
horn neurons [26].
Overall, the JNK family of MAPK genes is perhaps the
least well-studied of the MAPK gene superfamily. Has-
sanzadeh et al. demonstrated that this gene was required
for the appearance of spinal cord “dark neurons” after
peripheral formalin injection, neurons which are thought
to have undergone excitotoxic injury [27]. It does appear
that spinal cord dorsal horn astrocytes are activated
after peripheral formalin injection [28]; astrocytes may
be the primary site of spinal Mapk8 expression as noted
above. To our knowledge, the role of Mapk8/JNK1 in
regulating late phase formalin behavior has not been
well studied. Our experiments are, therefore, the first to
demonstrate directly a role for Mapk8/JNK1 in spinal
cord sensitization after formalin injection.
One interesting feature of our findings was the inverse
correlation of spinal cord Mapk8 mRNA and JNK1 pro-
tein levels. Thus mouse strains with higher licking times
had greater spinal cord JNK1 protein levels as expected,
based on the reported relationship between JNK1 func-
tion and pain behaviors in other models. In addition,
blockade of JNK using a selective agent reduced late
phase formalin licking behavior. However, as demon-
strated by the negative correlation coefficient for the
mRNA-behavior relationship in Table 2 and confirma-
tory data in Figure 3, the behaviorally higher responding
strains had lower Mapk8 mRNA levels. These observa-
tions suggest that the steady state levels of JNK1 are
controlled by factors other than transcription. One pos-
sible factor would be the protein’s high stability result-
ing in a low turnover rate, as JNK1 is constitutively
expressed in the spinal cord [21]. Therefore, relatively
low levels of Mapk8 mRNA would be necessary to
maintain the steady state levels of the protein. Another
possibility would be that the genetic factor(s) explaining
the inter-strain formalin behavioral differences might
involve control of translation rather than transcription.
In this scenario, genetically regulated enhancement of
translation may lead to high protein levels with compen-
satory reduction in transcriptional activity thus lowering
mRNA levels. Control of translation is a complex pro-
cess [29]. Though our studies did not specifically
address mechanisms which could explain this phenom-
enon, micro RNA (miRNA) is an example of a type of
regulatory molecule potentially enhancing translation of
multiple genes simultaneously. Alternatively, under basal
conditions the Mapk8 would be under negative regula-
tion by the JNK1 and its substrates, as intense and pro-
longed JNK activation would result in programmed cell
death[30]. Members of the MKKs (MAPK kinases)
which activate JNK pathway are themselves under nega-
tive regulation by substrates of JNK, whilst MKPs (MAP
kinase phosphatase) which inhibit the pathway are posi-
tively regulated by some of the same substrates [31,32].
It is notable that our haplotypic analysis was only
weakly suggestive of a role for Mapk8 genetics in con-
trolling late phase formalin behavior. In fact two of the
other associated genes also had strongly negative corre-
lations between mRNA levels and behavior.
While our experiments focused on Mapk8,o n eo t h e r
gene (Pla2g4e) was statistically even more closely linked
to formalin test second phase behaviors. This gene
codes for a cytosolic form of phospholipase A2 (PLA2),
an enzyme family with strong links to inflammatory
pain. PLA2 serves to liberate arachidonic acid which is
subsequently metabolized by cyclooxygenase 1 and 2
(COX1/COX2) to form pro-nociceptive prostanoids,
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ways as well. This enzyme family is comprised of
approximately 15 groups and four main types, including
the secreted sPLA2, cytosolic cPLA2, calcium-indepen-
dent iPLA2, and platelet activating factor (PAF) [33].
Though the Pla2g4e isoform has not been examined
specifically in pain models, cytosolic PLA2 probably
does contribute to spinal sensitization in several models
of pain. For example, the cytosolic PLA2 inhibitor,
AACOCF3, reduced both nociceptive sensitization and
spinal arachidonic acid production in the spinal cord tis-
sue of rats used in the chronic constriction injury model
of neuropathic pain [34]. In another set of experiments
it was demonstrated that antisense knockdown of spinal
cytosolic group 4a PLA2 reduced late but not early
phase formalin-induced pain behaviors [35]. This form
of phospholipase A2 is the predominant one in spinal
cord tissue [36]. In the same group of studies it was
determined that spinal cord dorsal horn neurons may be
the predominant site of spinal expression of this
enzyme. While the results from our study associated a
distinct member of the same cytosolic type of PLA2,
independent confirmation of this association is required.
Unfortunately the pharmacological and immunohisto-
chemical tools currently available would not provide
definitive evidence for the participation of Pla2g4e in
late phase formalin behavior, and it is likely that experi-
ments with knockout mice or spinal knock-down would
need to be performed.
Another associated gene with pre-existing data linking
its function to formalin late phase behaviors is the
Scn2b gene coding for the sodium ion channel b2 subu-
nit. The b subunits of sodium ion channels modulate
the kinetics and other electrical properties of sodium
ion channels [37]. In a recent report in which Scn2b
knockout animals and neurons derived from these ani-
mals were studied, it was discovered that Scn2b deletion
both reduced TTX-sensitive sodium ion currents in
small diameter neurons, and the expression of specific
sodium ion channels, notably NaV1.7 [38]. Critically,
gene deletion reduced late phase formalin behaviors
without altering early phase responses. Interestingly,
NaV1.7 is an ion channel whose dysfunction in humans
has been associated with either pain hypersensitivity or
insensitivity depending on the type of genetic alteration
present [39].
Conclusions
In this report we began with the nocifensive behavior
data for a relatively modest number of inbred mouse
strains, and using an expression dataset from spinal
cord tissue we were able to identify several highly plau-
sible genes for controlling late phase formalin test beha-
vior. Note that this strategy, like conventional QTL
mapping and haplotypic analysis, differs from other
molecular genetic techniques in that it can identify
genes contributing to trait variability and not just genes
that are trait-relevant. The use of confirmatory expres-
sion and pharmacological studies identified Mapk8/
JNK1 as a key regulator of variable second phase forma-
lin test pain behavior. In addition to the value of identi-
fying this specific target for potential analgesic
development, we have provided evidence demonstrating
the utility of undertaking this type of correlative study
to uncover pain-related signaling mechanisms. The
same method if applied to other sorts of pain models
might involve the use of expression datasets based on
alternative tissues (e.g., dorsal root ganglion) or data
sets constructed from animal tissues enduring more
chronic pain states (e.g., nerve injury models). Unavoid-
able, however, will be the need for strong confirmatory
data regardless of the technique used to establish the
preliminary association. Correlative expression analysis
appears to be a viable approach in the expanding realm
of genetic approaches to understanding pain
mechanisms.
Methods
Animals
Mice for all experiments were purchased from The Jack-
son Laboratory (Bar Harbor, ME) at 6-12 weeks of age,
or bred in-house from stock mice so obtained. Upon
weaning (at 18-21 d) or immediately after arrival, mice
were housed in standard shoebox cages of 2-4 with
same sex littermates in a temperature-controlled (20° ±
1°C) environment (14 h: 10 h light/dark cycle; lights on
at 07:00 h), and with ad lib access to food and water.
Purchased mice were habituated to the laboratory for at
least one week before any behavioral testing com-
menced. Husbandry conditions were similar for mice
housed at the McGill University and Palo Alto VA Med-
ical Center (VAPAHCS). All experiments were approved
by the local Institutional Animal Care and Use Commit-
tees of McGill University and VAPAHCS.
Formalin test
Mice were habituated in individual transparent Plexiglas
cylinders prior to a subcutaneous injection of 5% forma-
lin into the plantar right hindpaw (20 μl volume). Fol-
lowing injection mice were digitally videotaped from
underneath a glass floor for 60 min, or directly
observed. Video files were later sampled for 5 s at 1-min
intervals, and the presence or absence of right hindpaw
licking/biting nocifensive behaviors in that 5-s period
was scored using Observer software (Noldus, Leesburg,
VA). Direct observations timed the licking/biting beha-
vior using a stopwatch. The early phase of the formalin
test was defined as 0-5 min post-injection, and the late
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tabulated as the percent of samples licking during the
specified intervals. In pharmacological experiments mice
were continuously observed providing the total number
of seconds spent licking/biting in each phase for each
animal.
Drug administration
The non peptide JNK inhibitor, SP600125 (anthra [1,9-
cd]pyrazol-6(2H)-one), was purchased from Sigma (St.
Louis, MO) and prepared in DMSO (20% final concen-
tration). Intrathecal (i.t.) injections of 5 μl of SP600125
or vehicle (20% DMSO) were made under brief isofluor-
ane anesthesia with a 30-gauge needle between the L5
and L6 level as we have described previously[17]. The
SP600125 dose of 50 nmol was chosen from the results
of pilot experiments showing this to be a dose providing
maximal effect on late phase formalin behaviors, and
from the available literature [21]. Formalin injections
were performed 3 h after i.t. drug injections at which
time drug effect was found to be maximal, in agreement
with published data [21].
Expression analysis of mouse spinal cord tissue
Microarray analyses were performed using Affymetrix
GeneChip Mouse Genome 430 2.0 Array (>39,000 tran-
scripts) using previously described methods [40]. Spinal
cords were prepared from 3 experimentally naïve mice
from each of the following 10 inbred strains: 129/SvIm,
AKR, B10.D2-H2/oSNJ, BALB/c, C3H/He, C57BL/6,
DBA/2, LP, MRL/Mp, NZW/LaC (all “J” substrains).
The probe intensity data generated from all 30 arrays
were read into the R software environment http://www.
R-project.org directly from .CEL files using the R/affy
package [41], which was also used to extract and manip-
ulate probe level data to assess data quality and to cre-
ate expression summary measures. Normalization was
carried out using the robust multiarray average (RMA)
method [42] to form one expression measure for each
probeset on each array.
Each array has 45,101 probesets, which correspond to
>39,000 transcripts. The following analyses were applied
to identify probesets that were differentially expressed
between strains (with a >3-fold difference). A one-way
ANOVA model was applied to test whether the probeset
was differentially expressed among the mouse strains.
The average expression level for each probeset for each
strain was calculated. Since RMA signals are on log2
scale, the fold change was defined as 2 to the power of
the maximum average expression level minus the mini-
mum expression level. Probesets with ANOVA p < 0.01
and a fold change greater than 3 were identified as
genes that were significantly differentially expressed.
There were 2,500 probesets that met these criteria, and
these were selected for further correlational analysis
with the formalin test late phase data.
Correlational analysis of spinal cord expression and
mouse behavioral data
We assessed the extent of correlation between each
selected differentially expressed probeset and the pheno-
types of interest using Pearson’s correlation coefficient
[43]. For each probeset, the RMA signal intensity (at
log2 scale) was used for the correlation calculation. The
probesets were then ordered by the absolute value of
the correlation coefficient.
Genomic analysis
The SNP data provided by Frazer at al. were used to
identify the haplotypic structure around the Mapk8
gene [18]. Twelve strains were represented in this data-
base. In addition, BALB/cBy data were available, and
though we actually tested BALB/c mice, these substrains
were considered genetically similar enough to include
them in our haplotypic analysis. The murine Mapk8
gene is located on chromosome 14 from 34,191,084 to
34,260,344 bp (http://www.ensembl.org, Mouse Genome
Build 37). SNP data were downloaded from http://
mouse.perlegen.com/mouse/index.html, and all SNPs
that were within 2,000 bp of the Mapk8 region were
identified. There were 86 SNPs that were specific to the
8 strains within this genomic region, which included the
whole Mapk8 gene. The haplotypic structure of this
region was then visualized in Excel using a simple color-
ing scheme.
Halpotypic analysis was performed as outlined by
Wang et al. [19] using the strain specific Mapk8 asso-
ciated haplotype alleles. To test the degree of correlation
between the strain data and the allelic identities an
ANOVA based approach was used.
Expression analysis (mRNA)
Mice were killed at specific time points by CO2 asphyx-
iation without prior exposure to formalin. Spinal cord
tissue was harvested by extrusion. Lumbar spinal cord
segments were dissected on a chilled surface. Dissected
tissue was then quick-frozen in liquid nitrogen and
stored at -80°C until use. For PCR experiments, total
RNA was isolated using the RNeasy Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer’si n s t r u c -
tions. The purity and concentration were determined
spectrophotometrically as described previously for brain
and spinal cord samples [44]. In the next step cDNA
was synthesized from1 μg total RNA using random hex-
amer priming and a First Strand cDNA Synthesis Kit
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instructions. Quantitative PCR reactions were
conducted in a volume of 4 μl using the Sybr Green I
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Using an ABI prism 7900HT system (Applied Biosys-
tems, Foster City, California, USA), PCR was carried out
using the parameters 52°C, 5 min->95°C, 10 min then
(95°C, 30 s->60°C, 60 s) for 40 cycles. The sequences for
the Mapk8 primers were (forward primer) GCCA-
CAAATCCTCTTTCCA and (reverse primer)
CACATCGGGGAACAGTTTCT. Samples were ana-
lyzed in triplicate. Melting curves were performed to
document single product formation.
Quantification was accomplished according to the
standard curve method as described by the PCR system
manufacturer (PE Applied Biosystems) as we have used
previously [45]. In order to achieve the same PCR effi-
ciency for each analyte, serial dilution of cDNA was
used to construct standards curve for Mapk8 and 18S
RNA which was used as a control. The r
2 values for the
standard curves of the genes approached 1.0, suggesting
the same amplification efficiency in the PCR reactions
under these conditions.
Expression analysis (protein)
Lumbar spinal cord tissue was homogenized in SDS
Lyses sample Buffer, 100 mg tissue to 1 ml sample lysis
buffer mix (1.25 ml of 0.5 M Tris -HCL pH 6.8, 1 ml of
glycerol, 1 ml of 20% SDS, 69 μlo fb-mercaptoethanol,
6.68 ml distilled water, total 10 ml). Tissue was then
vortexed followed by boiling for 8 min, then cooling on
ice. The homogenate was centrifuged at 12,000 × g for
10 min at 4°C. The supernatant was collected and
retained for Western blot analyses. The concentration of
protein in the supernatant was measured using the DC
Protein Assay kit (Bio-Rad,H e r c u l e s ,C A ) .E q u a l
amounts of protein (50 μg) were sized fractionated by
electrophoresis on 10% acrylamide gels (Bio-Rad) and
transferred onto LI-COR Odyssey Nitrocellulose Mem-
brane (LI-COR Biosciences, Lincoln, NE). The blot was
blocked for overnight in LI-COR Odyssey Blocking Buf-
fer followed by incubation with a mixture of primary
antibodies. JNK1 affinity purified rabbit polyclonal anti-
body was used at 1:500 dilution (Abgent, San Diego,
CA) and actin mouse monoclonal antibody at 1:1000
dilution (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) with incubation on a rocking platform at 4°C for 24
h. After washing, the blots were incubated 2 h at room
temperature in a secondary antibody mix: IRDYE 680
donkey anti-mouse IgG (LI-COR) and IRDYE 800CW
goat anti rabbit IgG (LI-COR) at 1:20,000 dilution for
each. The blots were washed and placed in a LI-COR
Odyssey Infrared Imaging System. Bands specific to
each protein were quantified from the same gels and
analyzed with LI-COR software.
Statistical analysis
Frequency of, or total time spent licking the hindpaw as
w e l la st h et i m ec o u r s ed a t aw e r ea n a l y z e db yt w o - w a y
ANOVA followed by post-hoc Bonferroni multiple com-
parison tests. A criterion a = 0.05 was employed. For
expression analysis (mRNA and protein) experiments
samples from n = 4 mice per strain were analyzed in tri-
plicate. The values from three strains within each group
(replicates) were compared to other strain group (High
vs. low responding) by unpaired t-Test.
List of Abbreviations
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